Alflorex® is the only PrecisionBiotic™ supplement in Ireland to contain the unique and patented culture Bifidobacterium infantis 35624.
Discovered in Ireland.
Developed for Ireland.
For best results, take Alflorex daily for 4 weeks or more as part of a good lifestyle.
You may experience temporary changes in bowel habits as you begin to take Alflorex.
Alflorex, convenient and easy to use:
- Available over-the-counter, no prescription needed
- Only 1 capsule per day, taken with or without food
- For best results take Alflorex® daily for at least 4 weeks
- No refrigeration required
Alflorex is unique because it is the only product in Ireland to contain the PrecisionBiotic™ B. infantis 35624, which is backed by over 15 years of research and over 50 peer reviewed publications.
Alflorex was originally researched and co-developed by Scientists, Clinicians and Gastroenterologists in Alimentary Health Ltd. and University College Cork (one of the world’s leading institutions in research).
PrecisionBiotic™ cultures are elite bacterial strains which have been selected to have targeted action where needed.
Healthcare professionals - a section of our website has been designed especially for you! Take a look at the research supporting B. infantis 35624 and some key findings in these publications. In this section we point out some important facts when recommending a probiotic and what to look for.
There are some free learning tools that we have provided in this section to help you understand the PrecisionBiotic™ strain containing B. infantis 35624, such as our Study Summaries. For healthcare professionals having difficulties diagnosing digestive imbalance, there is a helpful quiz in this section that can help you to identify patients that may be suffering from digestive imbalance. This quiz has been designed by Professor Eamonn Quigley* according to the Rome III Diagnostic Criteria. Diet recommendations are also supplied, which can help healthcare professionals provide some helpful diet tips on digestive health.
To gain access to this content and further material, please click the button below.Healthcare Professional access
*Professor Quigley is one of the early investigators of B. infantis 35624 and Chief of Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Professor of Medicine, Weill Cornell College of Medicine, Houston, Texas. He is also a Principal Investigator at the Alimentary Pharmabiotic Centre (APC) at University College Cork (UCC).